title: Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial.
abstract: BACKGROUND
  Noninvasive methods are needed to evaluate reperfusion success in patients with acute myocardial infarction (MI). The AMISTAD trial was analyzed to compare MI size and myocardial salvage determined by electrocardiogram (ECG) with technetium Tc 99m sestamibi single-photon emission computerized tomography (SPECT) imaging.
  
  
  METHODS
  Of 236 patients enrolled in AMISTAD, 166 (70 %) with no ECG confounding factors and no prior MI were included in this analysis. Of these, group 1 (126 patients, 53%) had final infarct size (FIS) available by both ECG and SPECT. Group 2 (56 patients, 24%) had myocardium at risk, FIS, and salvage index (SI) assessed by both SPECT and ECG techniques. Aldrich/Clemmensen scores for myocardium at risk and the Selvester QRS score for final MI size were used. Salvage index was calculated as follows: SI = (myocardium at risk-FIS)/(myocardium at risk).
  
  
  RESULTS
  In group 1, FIS was 15% (6, 24) as measured by ECG and 11% (2, 27) as measured by SPECT. In the adenosine group, FIS was 12% (6, 21) and 11% (2, 22). In the placebo group, FIS was 16.5% (7.5, 24) and 11.5% (3.0, 38.5) by ECG and SPECT, respectively. The overall correlation between SPECT and ECG for FIS was 0.58 (P = .0001): 0.60 in the placebo group (P = .0001) and 0.54 (P = .0001) in the adenosine group. In group 2, myocardium at risk was 23% (17, 30) and 26% (10, 50) with ECG and SPECT, respectively (P = .0066). Final infarct size was 17% (6, 21) and 12% (1, 24) (P < .0001). The SI was 29% (-7, 57) and 46% (15, 79) with ECG and SPECT, respectively (P = .0510).
  
  
  CONCLUSIONS
  The ECG measurement of infarct size has a moderate relationship with SPECT infarct size measurements in the population with available assessments. This ECG algorithm must further be validated on clinical outcomes.
authors.affiliation: Hospital Italiano, Buenos Aires, Argentina.
authors.forename: Alejandro
authors.initials: A
authors.lastname: Barbagelata
authors.forename: Marcelo F
authors.initials: MF
authors.lastname: Di Carli
authors.forename: Robert M
authors.initials: RM
authors.lastname: Califf
authors.forename: Jyotsna
authors.initials: J
authors.lastname: Garg
authors.forename: Yochai
authors.initials: Y
authors.lastname: Birnbaum
authors.forename: Liliana
authors.initials: L
authors.lastname: Grinfeld
authors.forename: Raymond J
authors.initials: RJ
authors.lastname: Gibbons
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Granger
authors.forename: Shaun G
authors.initials: SG
authors.lastname: Goodman
authors.forename: Galen S
authors.initials: GS
authors.lastname: Wagner
authors.forename: Kenneth W
authors.initials: KW
authors.lastname: Mahaffey
mesh_terms: D000241:Adenosine / Q000627:therapeutic use*; D004562:Electrocardiography; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D011446:Prospective Studies; D015912:Thrombolytic Therapy
chemical_list: D000241:Adenosine